MCO
67
3
NVDA
55
4
KMX
55
9
EBAY
43
3
NKE
30
2
STT
64
4
LUV
40
2
TXN
43
-3
AIV
51
4
CA
16
3
CFG
58
6
HD
49
5
IRM
68
5
LMT
29
2
SYY
45
2
MU
39
5
HUM
39
9
NOC
45
13
VZ
37
3
RL
72
3
MCO
67
3
NVDA
55
4
KMX
55
9
EBAY
43
3
NKE
30
2
STT
64
4
LUV
40
2
TXN
43
-3
AIV
51
4
CA
16
3
CFG
58
6
HD
49
5
IRM
68
5
LMT
29
2
SYY
45
2
MU
39
5
HUM
39
9
NOC
45
13
VZ
37
3
RL
72
3
Financhill
Back

Sarepta Therapeutics 10K Form

Sell
31

SRPT
Sarepta Therapeutics

Last Price:
124.92
Seasonality Move:
11.13%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SRPT News And Ratings

See the #1 stock for the next 7 days that we like better than SRPT

SRPT Financial Statistics

Sales & Book Value

Annual Sales: $1.24B
Cash Flow: $-14.23M
Price / Cash Flow: 0
Annual Sales: $11.30
Price / Book: 11.07

Profitability

EPS (TTM): 0.74000
Net Income (TTM): $47.3M
Gross Margin: $1.09B
Return on Equity: 5.37%
Return on Assets: 1.46%

Sarepta Therapeutics Earnings Forecast

Key Sarepta Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 28 years for SRPT is 87.91%.
  • The Selling, General & Administrative Expenses for SRPT have been equal to 38.76% of Gross Profit Margin.
  • The Research & Development expenses have been 70.57% of Revenue.
  • The Interest Expense is -4.11% of Operating Income.
  • The Net Earning history of SRPT is -43.11% of Total Revenues.
  • Per Share Earnings over the last 28 years have been positive in 14 years.

Sarepta Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SRPT
CUSIP: 803607
Website: sarepta.com

Debt

Debt-to-Equity Ratio: 1.14
Current Ratio: 3.9
Quick Ratio: 2.69

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 10.47

SRPT Technical Analysis vs Fundamental Analysis

Sell
31
Sarepta Therapeutics (SRPT) is a Sell

Is Sarepta Therapeutics a Buy or a Sell?